Cited by 783Pluripotent Stem Cells ResearchParkinson's Disease Mechanisms and TreatmentsGenetics, Aging, and Longevity in Model Organisms

Human iPSC-based modeling of late-onset disease via progerin-induced aging

Open access
Miller, Justine D., Ganat, Yosif M., Kishinevsky, Sarah, Bowman, Robert L., Liu, Becky, Tu, Edmund Y., Mandal, Pankaj K., Vera, Elsa +9 more·2013·Cell stem cell

Abstract

Reprogramming somatic cells to induced pluripotent stem cells (iPSCs) resets their identity back to an embryonic age and, thus, presents a significant hurdle for modeling late-onset disorders. In this study, we describe a strategy for inducing aging-related features in human iPSC-derived lineages and apply it to the modeling of Parkinson's disease (PD). Our approach involves expression of progerin, a truncated form of lamin A associated with premature aging. We found that expression of progerin in iPSC-derived fibroblasts and neurons induces multiple aging-related markers and characteristics, including dopamine-specific phenotypes such as neuromelanin accumulation. Induced aging in PD iPSC-derived dopamine neurons revealed disease phenotypes that require both aging and genetic susceptibility, such as pronounced dendrite degeneration, progressive loss of tyrosine hydroxylase (TH) expression, and enlarged mitochondria or Lewy-body-precursor inclusions. Thus, our study suggests that progerin-induced aging can be used to reveal late-onset age-related disease features in hiPSC-based disease models.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.stem.2013.11.006

Cites

290 of 290 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Induction of pluripotency in iPSCs resets the age signatures of the donor cells to a fetal stage.

    “However, induction of pluripotency in iPSCs resets the age signatures of the donor cells to a fetal stage (7–9).”

    From Modeling late-onset Alzheimer’s disease neuropathology via direct neuronal reprogramming (2024) · cites this paper as [8]

    The Results section, “Reprogramming reverts Age-Associated Markers to a ‘Young’ State,” reports that iPSCs from old donors lacked age-associated markers and resembled young-donor iPSCs. It does not establish that their age signatures were reset specifically to a fetal stage, and it notes that selection of cells with low marker expression cannot be ruled out. (LLM, conf=0.86)

    Experimental — accuracy not yet measured
  • Erasure of aging signatures and re-gaining of fetal identity represents a potent rescue in this study.

    “Cellular aging features (Huh et al., 2016; Mertens et al., 2015a, 2018; Tang et al., 2017; Victor et al., 2014) and adult-like neuronal identity of iNs (Luo et al., 2019) are likely critical for the emergence of such phenotypes in sporadic AD neurons, because erasure of aging signatures and re-gaining of fetal identity represents a potent rescue in this study (Miller et al., 2013; Ocampo et al., 2”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 291 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Miller, J. D., Ganat, Y. M., Kishinevsky, S., Bowman, R. L., Liu, B., Tu, E. Y., Mandal, P. K., Vera, E., Shim, J.-W., Kriks, S., Taldone, T., Fusaki, N., Tomishima, M. J., Krainc, D., Milner, T. A., Rossi, D. J., & Studer, L.
Affiliations
  • Memorial Sloan Kettering Cancer Center (US)
  • Boston Children's Hospital (US)
  • Keio University (JP)
  • Harvard University (US)
  • Weill Cornell Medicine (US)
Corresponding author
Studer, Lorenz
Venue
Cell stem cell
Publisher
Elsevier BV
Published
2013-12
Volume
13
Issue
6
Pages
691-705
ISSN
  • 1875-9777 (ISSN-L)
  • 1934-5909
OpenAlex
W2081914422
Cited by
777
References
291
Citations by year
2026: 46 · 2025: 41 · 2024: 52 · 2023: 54 · 2022: 50 · 2021: 71 · 2020: 66 · 2019: 64 · 2018: 76 · 2017: 72 · 2016: 94 · 2015: 52 · 2014: 38 · 2013: 1
FWCI
27.60
Type
journal article
Language
en
Open access
Locations
  • Cell stem cell (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Science Foundation
  • New York Stem Cell Foundation
  • Memorial Sloan-Kettering Cancer Center
  • National Institutes of Health
  • National Heart, Lung, and Blood Institute (HL-098351, R01HL098351)
  • National Institute on Drug Abuse (R01DA008259, DA08259)
  • National Cancer Institute (F31CA167863, P30CA008748)
  • National Institute of Neurological Disorders and Stroke (NS078338, U24NS078338, R01NS052671, R01NS076054, NS076054)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
  • Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
Keywords
progerin, lamin A, premature aging, induced pluripotent stem cells, Parkinson's disease, late-onset disease, iPSC-derived fibroblasts, dendrite degeneration, tyrosine hydroxylase, Lewy bodies, mitochondrial enlargement, disease modeling
MeSH terms
Adult, Aged, Aged, 80 and over, Aging, Animals, Cell Differentiation, Child, Fibroblasts, Humans, Mesencephalon, Middle Aged, Models, Biological, Nuclear Proteins, Parkinson Disease, Phenotype, Protein Precursors, Tissue Donors, Biomarkers, Cellular Senescence, Age of Onset, Lamin Type A, Mice, Induced Pluripotent Stem Cells, Dopaminergic Neurons, Cellular Reprogramming

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review